5-氯-2-氟苯甲醛 | 96515-79-6

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯甲醛系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-氯-2-氟苯甲醛
• 中文别名: 5-氯-2-苯甲醛；2-氟-5-氯苯甲醛
• 英文名称: 5-chloro-2-fluorobenzaldehyde
• 英文别名: 2-fluoro-5-chlorobenzaldehyde
• CAS: 96515-79-6
• 化学式: C₇H₄ClFO
• mdl: MFCD03094518
• 分子量: 158.56
• InChiKey: WDTUCEMLUHTMCB-UHFFFAOYSA-N

物化性质

• 熔点：
  29-32℃
• 沸点：
  210.1±20.0 °C(Predicted)
• 密度：
  1.352±0.06 g/cm3(Predicted)
• 闪点：
  95℃
• 溶解度：
  溶于甲醇
• 稳定性/保质期：

  在常温常压下稳定，应避免与强氧化剂接触。

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 危险品运输编号：
  NONH for all modes of transport
• 危险标志：
  GHS07
• 危险性描述：
  H302,H412
• 危险性防范说明：
  P273
• 储存条件：
  密封保存，应储存在阴凉干燥的仓库中，并远离氧化剂。

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : 5-Chloro-2-fluorobenzaldehyde
CAS-No. : 96515-79-6
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Acute toxicity, Oral (Category 4)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Harmful if swallowed.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
Precautionary statement(s) none
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R22 Harmful if swallowed.
S-phrase(s) none
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C7H4ClFO
Molecular Weight : 158,56 g/mol
Component Concentration
5-Chloro-2-fluorobenzaldehyde
CAS-No. 96515-79-6 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, Hydrogen chloride gas, Hydrogen fluoride
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the
environment must be avoided.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Store under inert gas.
Specific end use(s)
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 34 - 39 °C
point
f) Initial boiling point and 120 °C at 1 hPa
boiling range
g) Flash point 95 °C
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 2,361
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion Harmful if swallowed.
Skin
May be harmful if absorbed through skin. May cause skin irritation.
Eyes Causes eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
Harmful to aquatic life.
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine Pollutant: no IATA: no
Special precautions for user
no data available

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
no data available

---

Section 16. OTHER INFORMATION
Further information
Copyright 2012 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  5-氯-2-氟苯甲醛 在 3-苄基羟乙基甲基噻唑氯化锂 、 potassium carbonate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 、 N,N-二甲基乙酰胺 为溶剂， 反应 4.5h， 生成 2-chlorodibenzo[b,f]oxepine-10,11-dione
  参考文献：
  名称：

  N-杂环卡宾（NHC）催化的分子内安息香缩合-氧化

  摘要：

  NHC催化的分子内安息香缩合-氧化技术是在环境条件下，以良好至极佳的收率，方便地合成掺入二苯并稠合七元杂环的各种环状1,2-二酮。提出的卡宾催化的转化似乎通过安息香中间体进行，然后进行好氧氧化。

  DOI：

  10.1039/d0ob02606a
• 作为产物：
  描述：

  5-氯-2-氟甲苯 在 chromium(VI) oxide 、 硫酸 、 乙酸酐 作用下， 反应 2.0h， 生成 5-氯-2-氟苯甲醛
  参考文献：
  名称：

  具有4-（二取代苯基）环和氨基烷基酯基的1,4-二氢吡啶衍生物的合成和降压活性：高效且持久的钙拮抗剂。

  摘要：

  合成了带有4-（二取代的苯基）环和氨基乙基酯或氨基-2,2-二甲基-丙基酯的新的1,4-二氢吡啶衍生物，并在血压正常的大鼠和自发性高血压的大鼠中检查了它们的降压活性。讨论了苯基取代基和酯基对降压活性的影响。几种化合物显示出比尼卡地平更有效的降压活性，大多数化合物具有更长的作用时间。其中，7B.HCl（TC-81）表现出强效和持久的活性，被选作进一步药理研究的候选药物。

  DOI：

  10.1248/cpb.40.2049

文献信息

• One-pot synthesis of substituted indolo[1,2-a]quinolines under transition-metal-free conditions
  作者：Adisak Thanetchaiyakup、Hassayaporn Rattanarat、Nutthawat Chuanopparat、Paiboon Ngernmeesri

  DOI：10.1016/j.tetlet.2018.01.085

  日期：2018.3

  A simple and efficient one-pot synthesis of substituted indolo[1,2-a]quinolines under transition-metal-free conditions has been developed. When 2-fluorobenzaldehyde was treated with substituted 2-methylindoles in the presence of Cs2CO3, the desired products were typically obtained in good to excellent yields. This reaction sequence involves a nucleophilic aromatic substitution and a Knoevenagel condensation

  已经开发了一种在无过渡金属条件下简单高效的一锅合成取代吲哚[1,2- a ]喹啉的方法。当在Cs 2 CO 3存在下用取代的2-甲基吲哚处理2-氟苯甲醛时，通常以良好或优异的产率获得所需产物。该反应序列涉及亲核芳族取代和Knoevenagel缩合反应。我们的机理研究表明，第一步中两个反应都可能以分子间反应的形式进行。
• [EN] CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME<br/>[FR] COMPOSÉS CARBAMATES ET LEUR PROCÉDÉ DE FABRICATION ET D'UTILISATION
  申请人：ABIDE THERAPEUTICS

  公开号：WO2013142307A1

  公开（公告）日：2013-09-26

  Provided herein are carbamate compounds which may be useful in the treatment of, for example, pain, solid tumors and/or obesity.

  本文提供的是可能在治疗疼痛、实体肿瘤和/或肥胖等方面有用的氨基甲酸酯化合物。
• Synthesis and biological activity of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 2: 2′-Substituted triclosan derivatives
  作者：Joel S. Freundlich、Min Yu、Edinson Lucumi、Mack Kuo、Han-Chun Tsai、Juan-Carlos Valderramos、Luchezar Karagyozov、William R. Jacobs、Guy A. Schiehser、David A. Fidock、David P. Jacobus、James C. Sacchettini

  DOI：10.1016/j.bmcl.2006.01.051

  日期：2006.4

  2'-Substituted analogs of triclosan have been synthesized to target inhibition of the key malarial enzyme Plasmodium falciparum enoyl acyl carrier protein reductase (PfENR). Many of these compounds exhibit good potency (EC50<500 nM) against in vitro cultures of drug-resistant and drug-sensitive strains of the P. falciparum parasite and modest (IC50=1-20 microM) potency against purified PfENR enzyme

  合成了2'-取代的三氯生类似物以靶向抑制关键的疟疾酶恶性疟原虫烯酰基酰基载体蛋白还原酶（PfENR）。这些化合物中的许多化合物对恶性疟原虫寄生虫的耐药菌株和药物敏感菌株的体外培养均显示出良好的效价（EC50 <500 nM），对纯化的PfENR酶具有适度（IC50 = 1-20 microM）的效价。与三氯生相比，本次2'-取代衍生物调查显示，其寄生虫的3D7和Dd2菌株分别获得了20倍和30倍以上的收益。
• Identification of ABX-1431, a Selective Inhibitor of Monoacylglycerol Lipase and Clinical Candidate for Treatment of Neurological Disorders
  作者：Justin S. Cisar、Olivia D. Weber、Jason R. Clapper、Jacqueline L. Blankman、Cassandra L. Henry、Gabriel M. Simon、Jessica P. Alexander、Todd K. Jones、R. Alan B. Ezekowitz、Gary P. O’Neill、Cheryl A. Grice

  DOI：10.1021/acs.jmedchem.8b00951

  日期：2018.10.25

  of hexafluoroisopropyl carbamate-based irreversible inhibitors of MGLL, culminating in a highly potent, selective, and orally available, CNS-penetrant MGLL inhibitor, 28 (ABX-1431). Activity-based protein profiling experiments verify the exquisite selectivity of 28 for MGLL versus other members of the serine hydrolase class. In vivo, 28 inhibits MGLL activity in rodent brain (ED50 = 0.5-1.4 mg/kg)

  丝氨酸水解酶单酰基甘油脂酶（MGLL）将内源性大麻素受体激动剂2-花生四烯酰基甘油（2-AG）和其他单酰基甘油转化为脂肪酸和甘油。MGLL的遗传或药理失活导致中枢神经系统2-AG升高，花生四烯酸和类二十烷酸相应减少，从而产生抗伤害性，抗焦虑和抗神经炎作用，而没有引起直接大麻素受体激动剂的全部精神活性作用。在这里，我们报告了基于六氟异丙基氨基甲酸酯的MGLL不可逆抑制剂的优化，最终形成了一种高效，选择性和口服的CNS渗透性MGLL抑制剂28（ABX-1431）。基于活性的蛋白质谱分析实验证明了MGLL与丝氨酸水解酶类别的其他成员相比具有28的出色选择性。在体内，28在鼠福尔马林疼痛模型中抑制了啮齿动物大脑中的MGLL活性（ED50 = 0.5-1.4 mg / kg），增加了大脑2-AG的浓度，并抑制了疼痛行为。ABX-1431（28）目前正在人类临床试验中进行评估。
• [EN] NOVEL COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION<br/>[FR] NOUVEAUX COMPOSÉS POUR LE TRAITEMENT DE MALADIES LIÉES À L'EXPRESSION DE DUX4
  申请人：FACIO INTELLECTUAL PROPERTY B V

  公开号：WO2021105481A1

  公开（公告）日：2021-06-03

  The present invention relates to compounds that act as DUX4 repressors, suitable for the treatment of diseases related to DUX4 expression, such as muscular dystrophies. It also relates to use of such compounds, or to methods of use of such compounds.

  本发明涉及作为DUX4抑制剂的化合物，适用于治疗与DUX4表达相关的疾病，如肌肉萎缩症。它还涉及使用这些化合物，或者使用这些化合物的方法。